Keith Houser - Biotech Medics Chairman Pres
BMCS Stock | USD 0.02 0.00 0.00% |
Insider
Keith Houser is Chairman Pres of Biotech Medics Ne
Age | 74 |
Phone | 972-274-5533 |
Web | https://biotecmedics.com |
Similar Executives
Showing other executives | INSIDER Age | ||
CSC MD | Shuttle Pharmaceuticals | 57 | |
Ken Gelhaus | Alpha Teknova | 40 | |
Paul Blanchfield | Lantheus Holdings | 44 | |
Adel Mekhail | Prestige Brand Holdings | 64 | |
Alexander Schobel | Aquestive Therapeutics | 66 | |
David Francisco | Organogenesis Holdings | 59 | |
Albert Bolles | Lifecore Biomedical | 67 | |
Muthusamy RPh | ANI Pharmaceuticals | 57 | |
Mira Jung | Shuttle Pharmaceuticals | 76 | |
Dean Siegal | Prestige Brand Holdings | N/A | |
Meg Smith | Dynavax Technologies | N/A | |
CPA CPA | Intracellular Th | 68 | |
Jean Filippi | Phibro Animal Health | N/A | |
Peter Langosh | Amphastar P | 71 | |
Eric Dadey | Aquestive Therapeutics | N/A | |
Floyd MD | Alkermes Plc | 88 | |
Zorina Pitkin | Organogenesis Holdings | N/A | |
Yongfeng Zhang | Amphastar P | 78 | |
Jude Onyia | Neurocrine Biosciences | 61 | |
Damian Finio | Phibro Animal Health | 54 | |
Patrick Bilbo | Organogenesis Holdings | 63 |
Biotech Medics Ne Leadership Team
Elected by the shareholders, the Biotech Medics' board of directors comprises two types of representatives: Biotech Medics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotech. The board's role is to monitor Biotech Medics' management team and ensure that shareholders' interests are well served. Biotech Medics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotech Medics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Houser, Chairman Pres | ||
James Nairne, Chief Officer | ||
Anthony Miller, Chief Officer | ||
Tom Wood, VP Sales |
Biotech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biotech Medics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Profit Margin | (1.29) % | |||
Operating Margin | (1.24) % | |||
Current Valuation | 9.68 M | |||
Shares Outstanding | 172.36 M | |||
Price To Earning | (0.47) X | |||
Price To Sales | 3.30 X | |||
Revenue | 469.8 K | |||
Gross Profit | 408.14 K | |||
EBITDA | 33.35 K | |||
Net Income | (603.72 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biotech Pink Sheet Analysis
When running Biotech Medics' price analysis, check to measure Biotech Medics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Medics is operating at the current time. Most of Biotech Medics' value examination focuses on studying past and present price action to predict the probability of Biotech Medics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Medics' price. Additionally, you may evaluate how the addition of Biotech Medics to your portfolios can decrease your overall portfolio volatility.